Polyphor

Scroll
Investment area
Novo Seeds
Region
Europe
Date of investment
September 2018
Website
https://www.polyphor.com/

Polyphor is a clinical stage, Swiss biopharmaceutical company which has discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). OMPTA antibiotics target the highest priority Gram-negative ESKAPE pathogens, (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp) which are the leading cause of severe and often deadly infections throughout the world, such as bloodstream infections and pneumonia. Importantly, this new class of antibiotics is active against strains, which have become resistant to most – and in some cases all – commonly used antibiotics including the “last resort” antibiotic colistin.